Cargando…

Arterial methemoglobin level predicts therapeutic effectiveness of the PDE5 inhibitors in patients with in idiopathic pulmonary arterial hypertension

Detalles Bibliográficos
Autores principales:	Tamura, Yuichi, Ono, Tomohiko, Kawakami, Takashi, Kataoka, Masaharu, Sano, Motoaki, Satoh, Toru, Fukuda, Keiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363269/ http://dx.doi.org/10.1186/1471-2210-11-S1-P71

Ejemplares similares

Human Pentraxin 3 (PTX3) as a Novel Biomarker for the Diagnosis of Pulmonary Arterial Hypertension
por: Tamura, Yuichi, et al.
Publicado: (2012)

A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population
por: Kimura, Mai, et al.
Publicado: (2017)

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Pulmonary Artery Pressure as a Treatment Target to Improve the Prognosis of Idiopathic Pulmonary Arterial Hypertension　― Insight From a Cohort From Two Japanese Pulmonary Hypertension Centers ―
por: Ishiguro, Midori, et al.
Publicado: (2020)

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
por: Kimura, Mai, et al.
Publicado: (2015)

Erratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice
por: Kataoka, Masaharu, et al.
Publicado: (2019)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension
por: Murata, Mitsushige, et al.
Publicado: (2017)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

Successful depiction of systemic collateral supply to pulmonary artery in CTEPH using time-resolved 4D CT angiography: a case report
por: Tamura, Masashi, et al.
Publicado: (2020)

Genetic Testing Enables the Diagnosis of Familial Hypercholesterolemia Underdiagnosed by Clinical Criteria: Analysis of Japanese Early-Onset Coronary Artery Disease Patients
por: Miyama, Hiroshi, et al.
Publicado: (2023)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Therapeutic impact of dietary vitamin D supplementation for preventing right ventricular remodeling and improving survival in pulmonary hypertension
por: Tanaka, Hiroaki, et al.
Publicado: (2017)

Methemoglobin level as an indicator for disease severity in sepsis
por: Schuerholz, T, et al.
Publicado: (2008)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

A microsurgical technique for catheter insertion in the rat femoral artery
por: Sugai, Kazuhisa, et al.
Publicado: (2020)

TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
por: Shinya, Yoshiki, et al.
Publicado: (2021)

Cardiomyocyte-Specific Overexpression of HEXIM1 Prevents Right Ventricular Hypertrophy in Hypoxia-Induced Pulmonary Hypertension in Mice
por: Yoshikawa, Noritada, et al.
Publicado: (2012)

Autoimmune hypophysitis as a cause of adrenocorticotropic hormone deficiency in pulmonary arterial hypertension: a case report
por: Ichihara, Genki, et al.
Publicado: (2021)

Prognostic value of three-dimensional echocardiographic right ventricular ejection fraction in patients with pulmonary arterial hypertension
por: Murata, Mitsushige, et al.
Publicado: (2016)

Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR)
por: Tamura, Yuichi, et al.
Publicado: (2021)

TET2 Variants in Japanese Patients With Pulmonary Arterial Hypertension
por: Hiraide, Takahiro, et al.
Publicado: (2021)

THE PRODUCTION OF METHEMOGLOBIN BY PNEUMOCOCCI
por: Cole, Rufus
Publicado: (1914)

A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
por: Inami, Takumi, et al.
Publicado: (2014)

STUDIES ON THE OXIDATION-REDUCTION OF HEMOGLOBIN AND METHEMOGLOBIN : IV. THE INHIBITION OF "SPONTANEOUS" METHEMOGLOBIN FORMATION.
por: Neill, James M.
Publicado: (1925)

THE FORMATION OF METHEMOGLOBIN BY STREPTOCOCCUS VIRIDANS
por: Blake, Francis G.
Publicado: (1916)

Diffusivity Measurements of Human Methemoglobin
por: Keller, K. H., et al.
Publicado: (1966)

Differential effects of selective PDE5 inhibitors in rat cerebral arteries in vitro and in vivo
por: Kruuse, Christina, et al.
Publicado: (2009)

STUDIES ON THE OXIDATION-REDUCTION OF HEMOGLOBIN AND METHEMOGLOBIN : III. THE FORMATION OF METHEMOGLOBIN DURING THE OXIDATION OF AUTOXIDIZABLE SUBSTANCES.
por: Neill, James M.
Publicado: (1925)

Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011)

Factors related to instrumental activities of daily living in persons with chronic thromboembolic pulmonary hypertension
por: Iwasawa, Tatsuya, et al.
Publicado: (2021)

Long-term Follow-up of Qing-Dai–Induced Pulmonary Arterial Hypertension: A Case Series
por: Matsushima, Takahide, et al.
Publicado: (2023)

Reference values for methemoglobin concentrations in children
por: Rechetzki, Kely Francini, et al.
Publicado: (2012)

Impact of left ventricular late enhancement on pulmonary arterial hypertension in idiopathic dilated cardiomyopathy
por: Pérez-David, Esther, et al.
Publicado: (2015)

Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study
por: Kawakami, Takashi, et al.
Publicado: (2020)

STUDIES ON THE OXIDATION-REDUCTION OF HEMOGLOBIN AND METHEMOGLOBIN : II. THE OXIDATION OF HEMOGLOBIN AND REDUCTION OF METHEMOGLOBIN BY ANAEROBIC BACILLI AND BY STERILE PLANT TISSUE.
por: Neill, James M.
Publicado: (1925)

METHEMOGLOBIN FORMATION BY STERILE CULTURE FILTRATES OF PNEUMOCOCCUS
por: Morgan, Hugh J., et al.
Publicado: (1924)

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
por: Izumi, Keiichi, et al.
Publicado: (2022)

PDE3 is the major cGMP-PDE in adult mouse ventricular cardiomyocytes
por: Götz, Konrad R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_899o9r05h3a5v4bkffcrhcpqeo